biostudies-literatureUnknown63(SI2)Lovell DJBristol Myers Squibb<h4>Objective</h4>The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry.<h4>Methods</h4>The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<h4>Results</hRheumatology (Oxford, England)SI195-SI206https://www.ebi.ac.uk/biostudies/studies/S-EPMC11381685biostudies-literatureSafety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.PMC11381685Quartier PDe Ranieri Dfor PRINTO and the Pediatric Rheumatology Collaborative Study Group (PRCSG)§Cabral DAlexeeva ETerreri MTRosenkranz MGo EJames KWilliams CVersbsy JTaylor JNewhall LDalrymple AWaugaman BBohnsack JDel Rio AQCassidy EPatel JHuber ABohnsack JFHazel EBlakley MCartwright VBallinger STzaribachev NPenades ICMorishita KGillispie-Taylor MGitelman MKDare JStern SBarhula STrachana MKietz DWalters HLevy DPeroni DQuintero AChasnyk VHersh ARamanan AMoreno ESarychev AMiller MHuber AMCurran MSimon TAMoorthy NHashkes PPAlly MHui-Yen JAnton JPepmueller PInman CGuzman JGuzman MHenrickson MStanevicha VVehe RKStringer EBrunner HICornejo GVReiff ACompillo SOlivieri ANKelly LLovell DJEdens CHelling-Bakki AShaham BCorrell CBreedt JHoughton KHuggins JTreemarcki EGoldsmith DGotte AHerlin TKamphuis SParkinson EZeft ATuttle PJustice MRodriguez-Smith JFeller LLouw IMarzan KJerath ROrban ICarrasco RGastanaga MEPKingsbury DBrueck DRennebohm RWoodward ALuca NSchmeling HOliveira-Ramos FRamsey STarvin SSuccimarri RBrochard KSukumarain SHobday PHorwitz MMinden KZulian FSilverman EHiskey MBrunner JLang BAppenzeller SLeBlance CBrunner HArdalan KBrown DMehta JTing TCo DLvovich SMartini ANikishina ISchulert GNolan BWulffraat NSuwairi WMSDavis AGriffin TBoneparth AWhitaker COnel KTesher MFernandes TSharma NMiraval TRoth-Wojcicki ERuperto NKoskova EGrom ASpence SGottlieb BBinstadt BNocton JSteigerwald KSimonini GZelf APanupattanapong SDhalla MKlausmeier TGraham TWagner-Weiner LMian ZChedeville GToib DBrodus EVehe ROlson JRodriguez MJohnson NMontin DDel-Castillo PMSpalding SDurkee DUdaondo CGrebenkina LTorok KDeWitt EMMorris PChalom BBoulva SFHorneff GHufnagel MLazar CCostanzo DAlperin RFoeldvari IOliveira SVora SLasky ASyed RMoore TStevens BO'Neil KRobinson ALovell DTucker LGriffin TAStanevica VOliver MDominique AfalseSafety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.<h4>Objective</h4>The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry.<h4>Methods</h4>The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<h4>Results</h2024-01-01T00:00:00Z2024 Sep2026-07-15T08:06:29.155Z2025-04-04T00:28:51.4ZS-EPMC113816853824372210.1093/rheumatology/keae025